0
     

Report Added
Report already added
Analgesics in Switzerland

Analgesics in Switzerland

The hygiene and social distancing measures to control the spread of COVID-19, alongside periods of limited mobility, have likely contributed to reduced influenza and the transmission of other viral diseases transmission in Switzerland in 2022. Although higher than in the previous season, influenza activity, for example, has remained generally low in 2022, compared to previous seasons. Despite this, analgesics, which are extensively used to treat these types of affections, are posting positive va...

Euromonitor International's Analgesics in Switzerland report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2017-2021, allowing you to identify the sectors driving growth. Forecasts to 2026 illustrate how the market is set to change.

Product coverage: Systemic Analgesics, Topical Analgesics/Anaesthetic.

Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.

Why buy this report?
* Get a detailed picture of the Analgesics market;
* Pinpoint growth sectors and identify factors driving change;
* Understand the competitive environment, the market’s major players and leading brands;
* Use five-year forecasts to assess how the market is predicted to develop.
Analgesics in Switzerland

List Of Contents And Tables

ANALGESICS IN SWITZERLAND
KEY DATA FINDINGS
2022 DEVELOPMENTS
Positive performance seen, despite lower influenza and other respiratory virus activity
Topical analgesics/anaesthetic is the best performer, thanks to aging population in the country
Generic analgesics remain a niche, despite the high prices of branded medicines
PROSPECTS AND OPPORTUNITIES
Positive outlook for analgesics set to extend over the forecast period, driven by pandemic fallout and demographics
Analgesics expected to reach maturity as a category, leading to saturation and limitations
Potential distribution deregulation could lead to wider sales and lower prices
CATEGORY DATA
Table 1 Sales of Analgesics by Category: Value 2017-2022
Table 2 Sales of Analgesics by Category: % Value Growth 2017-2022
Table 3 NBO Company Shares of Analgesics: % Value 2018-2022
Table 4 LBN Brand Shares of Analgesics: % Value 2019-2022
Table 5 Forecast Sales of Analgesics by Category: Value 2022-2027
Table 6 Forecast Sales of Analgesics by Category: % Value Growth 2022-2027
CONSUMER HEALTH IN SWITZERLAND
EXECUTIVE SUMMARY
Consumer health in 2022: The big picture
2022 key trends
Competitive landscape
Retailing developments
What next for consumer health?
MARKET INDICATORS
Table 7 Consumer Expenditure on Health Goods and Medical Services: Value 2017-2022
Table 8 Life Expectancy at Birth 2017-2022
MARKET DATA
Table 9 Sales of Consumer Health by Category: Value 2017-2022
Table 10 Sales of Consumer Health by Category: % Value Growth 2017-2022
Table 11 NBO Company Shares of Consumer Health: % Value 2018-2022
Table 12 LBN Brand Shares of Consumer Health: % Value 2019-2022
Table 13 Penetration of Private Label in Consumer Health by Category: % Value 2017-2022
Table 14 Distribution of Consumer Health by Format: % Value 2017-2022
Table 15 Distribution of Consumer Health by Format and Category: % Value 2022
Table 16 Forecast Sales of Consumer Health by Category: Value 2022-2027
Table 17 Forecast Sales of Consumer Health by Category: % Value Growth 2022-2027
APPENDIX
OTC registration and classification
Vitamins and dietary supplements registration and classification
Self-medication/self-care and preventive medicine
Switches
Summary 1 OTC: Reverse Switches 2021-2022
DISCLAIMER
DEFINITIONS
SOURCES
Summary 2 Research Sources

Report Title: Analgesics in Switzerland


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW